Application of anti-angiogenesis medicine in improvement of retention rate of soft tissue graft
By using antiangiogenic drugs to inhibit vascularization in soft tissue transplantation, the negative impact of vascular growth on graft retention is solved, the retention rate of soft tissue grafts is improved, and more stable plastic surgery effect is provided.
Patent Information
- Application Number
- CN202410982317.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-08-17
- Filing Date
- 2024-07-22
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-07-22
AI Technical Summary
In soft tissue transplantation, vascular growth may have a negative impact on the retention of the graft, resulting in phagocytosis, disintegration and necrosis of the graft. The prior art is difficult to effectively reduce or avoid this problem.
Antiangiogenic drugs, such as VEGF monoclonal antibodies, soluble VEGFR, human VEGFR-2 monoclonal antibodies or small molecule tyrosine kinase inhibitors, inhibit the early vascularization of soft tissue grafts and weaken the body's immune response.
It effectively improves the retention rate of soft tissue grafts, reduces the appearance of inflammation and immune cells, and provides better plastic surgery results.
Smart Images

Figure CN119055769A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of plastic surgery, and in particular relates to the application of anti-angiogenesis drugs in improving the retention rate of soft tissue grafts. Background Art
[0002] Soft tissue defects and volume deficiency caused by aging, trauma or iatrogenic causes are common diseases in plastic surgery. Autologous soft tissue transplantation is one of the main means of treating plastic surgery diseases, but the unstable long-term retention rate of the graft is the biggest drawback limiting the application of this technology.
[0003] The retention rate of soft tissue grafts is related to many factors, and vascularization is considered to be a key factor. According to the classic "three-zone theory" of fat transplantation, fat grafts can be divided into: the outermost survival zone, the middle regeneration zone, and the inner necrotic zone according to the degree of vascular ingrowth. Traditional theory believes that in the process of tissue transplantation, blood vessels, as transportation channels for nutrients, play a vital role in promoting the retention and survival of transplanted tissues. Therefore, traditional theory believes that vascularization is usually required in tissue transplantation. For example, Ling Xiyue et al. (Ling Xiyue, Dong Hai. Research progress in improving the survival rate of autologous fat particle transplantation [J]. Journal of Yanbian University of Medicine, 2017, 40(2): 147-149.) believe that "the key to improving the survival rate of fat transplantation is to accelerate vascular reconstruction after transplantation and promote the differentiation of pre-adipocytes, which is closely related to the action of many factors. Research results in recent years have shown that vascular endothelial growth factor (VEGF), leptin, stromal vascular component cells (SVF), platelet-rich plasma (PRP), basic fibroblast growth factor (b-FGF), insulin and insulin-like growth factor-1, epidermal growth factor, platelet-derived growth factor and adrenaline can all promote the survival of transplanted fat." Li Zheng et al. (Li Zheng, Yu Panzhou, Liang Qiguo. Research progress on methods to improve the survival rate of autologous fat transplantation [J]. "Chinese Journal of Medical Cosmetology", 2021, 11(10): 87-90.) believe that "the survival rate of fat transplantation is not only related to the separation and purification of fat, but also depends on factors such as the location of the recipient area after transplantation, local blood supply, extracellular matrix, mature adipocytes, etc. After fat transplantation, sufficient blood supply and tissue perfusion are required to ensure that the transplanted cells obtain the oxygen and nutrients required for their survival. If the blood supply is insufficient, nutrients are lacking, and metabolic products are easily accumulated, the survival rate of fat transplantation in the recipient area will be greatly reduced. Therefore, promoting the differentiation of pre-adipocytes, accelerating the reconstruction of blood supply after transplantation, and improving tissue perfusion are of great significance to improving the survival rate of transplanted fat.
[0004] In addition, the patent with publication number CN107185046A discloses a method for increasing the survival rate of fat cell transplants, by treating a fat cell population with a sterile stabilizing reagent in vitro, adding autologous high-concentration platelet plasma PRP and recombinant human vascular endothelial growth factor VEGF-C to the fat cell population, stimulating the release of multiple cytokines, improving angiogenesis of adipose tissue and preventing apoptosis of fat grafts, thereby allowing the transplanted fat cells to survive during the production period.
[0005] However, the inventors have found in long-term clinical practice that, contrary to traditional cognition, in soft tissue transplantation, vascular ingrowth may have a negative impact on the retention of the graft. In the early stage of transplantation, the large number of immune and inflammatory cells brought by the blood vessels often lead to the phagocytosis, disintegration and necrosis of the graft. Therefore, how to reduce or avoid the negative impact of vascular ingrowth on the graft is a technical problem that needs to be solved in the field of plastic surgery. Summary of the invention
[0006] In order to solve the above-mentioned technical problems, improve the retention rate of soft tissue transplants, and thus ensure the surgical effect of plastic surgery, the present invention proposes the following technical solutions.
[0007] In one aspect, the present invention provides the use of an anti-angiogenesis drug in improving the retention rate of fat grafts.
[0008] Another aspect of the present invention provides the use of an anti-angiogenesis drug in preparing a product for improving the retention rate of soft tissue grafts.
[0009] Preferably, the anti-angiogenesis drug or the product is used in an animal transplanted with a soft tissue graft, or the anti-angiogenesis drug or the product is used to treat a soft tissue graft to be transplanted.
[0010] Preferably, the anti-angiogenic drug comprises one or more of VEGF monoclonal antibody, soluble VEGFR, humanized VEGFR-2 monoclonal antibody or small molecule tyrosine kinase inhibitor.
[0011] Furthermore, the VEGF monoclonal antibody includes bevacizumab, the soluble VEGFR includes aflibercept, the humanized VEGFR-2 monoclonal antibody includes ramucirumab, and the small molecule tyrosine kinase inhibitor includes etanercept.
[0012] Preferably, the dosage of the anti-angiogenesis drug is 1 mL of the soft tissue graft combined with 0.5-10 mg of the anti-angiogenesis drug.
[0013] Further, 1 mL of the soft tissue graft is combined with 1.25-6.25 mg of the bevacizumab, for example, 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 6.25 mg. For another example, 1 mL of the soft tissue graft is combined with 0.05-0.25 mL of the bevacizumab at a concentration of 25 mg / mL.
[0014] 1 mL of the soft tissue graft is combined with 2-10 mg of the aflibercept, for example, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg. For another example, 1 mL of the soft tissue graft is combined with 0.05-0.25 mL of the aflibercept at a concentration of 40 mg / mL.
[0015] 1 mL of the soft tissue graft is combined with 0.5-2.5 mg of the ramucirumab, for example, 0.5 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mg. For another example, 1 mL of the soft tissue graft is combined with 0.05-0.25 mL of the ramucirumab at a concentration of 10 mg / mL.
[0016] 1 mL of the soft tissue graft is combined with 1.0-2.5 mg of the orally administered Etan, for example, 1.0 mg, 1.25 mg, 1.50 mg, 1.75 mg, 2.0 mg, 2.25 mg, 2.5 mg.
[0017] Preferably, the soft tissue graft comprises one or more of a skin graft, a fat graft, a tendon graft, a muscle graft, a ligament graft, a joint capsule graft, a synovial capsule graft, a corneal graft or a nerve graft.
[0018] Preferably, the soft tissue graft is fat, more preferably autologous fat or allogeneic fat, and more preferably autologous fat.
[0019] Anti-angiogenic drugs can inhibit the early vascularization of fat grafts and reduce the body's immune response to fat grafts. Similar to the mechanism used in fat grafts, anti-angiogenic drugs can also inhibit the early vascularization of other soft tissue grafts and reduce the body's immune response, such as skin grafts, tendon grafts, muscle grafts, ligament grafts, joint capsule grafts, synovial capsule grafts, corneal grafts and nerve grafts.
[0020] In one embodiment of the present invention, the anti-angiogenesis drug and the soft tissue transplant are applied to animals, including humans and non-human mammals.
[0021] Preferably, the non-human mammals include mice, rabbits, cats, dogs, pigs, etc.
[0022] Beneficial effects of the present invention:
[0023] The present invention uses anti-angiogenic drugs to inhibit the early vascularization of soft tissue grafts, weakens the body's immune response to soft tissue grafts, thereby reducing inflammation and immune cells and improving the retention rate of soft tissue grafts. The present invention provides new ideas and technical means for plastic surgery and improves the retention effect of grafts after soft tissue transplantation surgery. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 The immunohistochemical staining result of the fat graft in Example 1 of the present invention, wherein the dark part is the stained blood vessel;
[0025] Figure 2 The statistical result of the number of blood vessels in the fat graft in Example 1 of the present invention;
[0026] Figure 3 The volume change result of the fat graft in Example 1 of the present invention;
[0027] Figure 4 This is the volume change curve of the fat graft in Example 1 of the present invention.
[0028] In the above figures, Bev represents the bevacizumab treatment group, Afl represents the aflibercept group, Ram represents the ramucirumab group, and Control represents the control group. DETAILED DESCRIPTION
[0029] The present invention is further described below in conjunction with the accompanying drawings and specific examples. These examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually performed according to conventional conditions in the art or according to conditions recommended by the manufacturer. Unless otherwise specified, all conventional methods are used. Unless otherwise defined, the professional and scientific terms used in the text have the same meanings as those familiar to those skilled in the art.
[0030] In the present invention, the term "soft tissue" refers to the parts of the animal body other than bones, including skin, fat, tendons, muscles, ligaments, joint capsules, synovial capsules, corneas and nerves.
[0031] In the present invention, the term "fat graft" refers to a substance derived from autologous or allogeneic fat tissue that is processed and used for filling.
[0032] In the present invention, the term "anti-angiogenic drug" refers to a drug that reduces or inhibits angiogenesis.
[0033] Example 1 Mouse fat transplantation experiment
[0034] 1.1 Preparation of fat graft
[0035] C57BL / 6 mice were killed by intraperitoneal injection of the anesthetic sodium pentobarbital (50 mg / kg), and the subcutaneous fat pads in the bilateral inguinal regions of the mice were removed and cut into very small pieces, which were collected into a syringe to obtain fat grafts.
[0036] 1.2 Fat graft retention experiment
[0037] C57BL / 6 male mice aged more than 8 weeks were selected as recipient mice and randomly divided into bevacizumab treatment group (Bev group), aflibercept treatment group (Afl group), ramucirumab treatment group (Ram group) and control group (Control group), with 7 C57BL / 6 recipient mice in each group. The prepared fat graft was subcutaneously injected into the back of each C57BL / 6 recipient mouse through an 18G syringe, and 0.3 mL of fat graft was injected at a single point in each mouse.
[0038] Each mouse in the Bev group was injected with 0.05 mL of 25 mg / mL bevacizumab on the back; each mouse in the Afl group was injected with 0.05 mL of 40 mg / mL aflibercept on the back; each mouse in the Ram group was injected with 0.05 mL of 10 mg / mL ramucirumab on the back; and each mouse in the Control group was injected with 0.05 mL of normal saline on the back. Seven mice in each group were killed on days 3, 7, 14, 21, 30, 60, and 90, respectively, and the fat grafts were removed.
[0039] 1.2.1 Immunohistochemical staining of vascular marker CD31 was performed. The results are shown in Figure 1 , Figure 2 and Table 1.
[0040] Table 1 Number of blood vessels in fat grafts (mean values)
[0041]
[0042] Depend on Figure 1 It can be seen that within the half-life of bevacizumab (21 days), the number of blood vessels in the fat grafts of the bevacizumab group was significantly less than that of the control group. However, as the mice were kept for longer than the half-life of bevacizumab after fat transplantation, the difference in the number of blood vessels between the bevacizumab group and the control group gradually narrowed, indicating that bevacizumab has a significant inhibitory effect on angiogenesis in fat grafts.
[0043] During the half-life of Aflibercept (7 days), the number of blood vessels in the fat grafts of the Aflibercept group was significantly less than that of the control group. However, as the mice were kept for longer than the half-life of Aflibercept after fat transplantation, the difference in the number of blood vessels between the Aflibercept group and the control group gradually narrowed, indicating that Aflibercept has a significant inhibitory effect on angiogenesis in fat grafts.
[0044] During the half-life of ramuciumab (14 days), the number of blood vessels in the fat grafts of the ramuciumab group was significantly less than that of the control group. However, as the mice were kept for longer than the half-life of ramuciumab after fat transplantation, the difference in the number of blood vessels between the ramuciumab group and the control group gradually narrowed, indicating that ramuciumab has a significant inhibitory effect on angiogenesis in fat grafts.
[0045] As shown in Table 1 and Figure 2 As shown, on the 3rd day after fat transplantation, the average number of blood vessels in the fat grafts of the bevacizumab group was 1.55, while that of the control group was 2.45. The number of blood vessels in the bevacizumab group was less than that of the control group, and the difference between the two groups reached a significant level (p < 0.05). On the 7th day after fat transplantation, the average number of blood vessels in the fat grafts of the bevacizumab group was 1.1, while that of the control group was 2.5. The number of blood vessels in the bevacizumab group was less than that of the control group, and the difference between the two groups was significant (p < 0.05). On the 14th day after fat transplantation, the average number of blood vessels in the bevacizumab group was 1.35, while that of the control group was 4.75. The number of blood vessels in the bevacizumab group was less than that of the control group, and the difference between the two groups was significant (p < 0.05). On the 21st day after fat transplantation, the average number of blood vessels in the bevacizumab group was 1.9, while that of the control group was 3.9. The number of blood vessels in the bevacizumab group was less than that of the control group, and the difference between the two groups was significant (p < 0.05). On the 30th day after fat transplantation, the average number of blood vessels in the Bevacizumab group was 2.2, while that in the Control group was 2.3. The number of blood vessels in the Bevacizumab group was less than that in the Control group, and the difference between the two groups was not significant (p>0.05). As the fat transplantation time was further extended, the number of blood vessels in the Bevacizumab group gradually decreased, while the number of blood vessels in the Control group gradually increased. On the 90th day after fat transplantation, the average number of blood vessels in the Bevacizumab group was 2.0, while that in the Control group was 2.66. The number of blood vessels in the Bevacizumab group was less than that in the Control group, and the difference between the two groups was not significant (p>0.05). Table 1 and Figure 2 The results showed that in the first 30 days after fat transplantation, the amount of angiogenesis in the fat grafts of the bevacizumab group was less than that in the control group. As the mice were fed for longer periods of time after fat transplantation, the difference in angiogenesis between the two groups gradually increased (before 14 days), and then gradually decreased (after 14 days), until the difference between the two groups became less obvious 30 days after fat transplantation, indicating that bevacizumab can effectively inhibit the angiogenesis of fat grafts.
[0046] On the 3rd day after fat transplantation, the average number of blood vessels in the fat grafts of the aflibercept group was 0.7, while that of the control group was 2.45. The number of blood vessels in the aflibercept group was less than that of the control group, and the difference between the two groups reached a significant level (p < 0.05). On the 7th day after fat transplantation, the average number of blood vessels in the fat grafts of the aflibercept group was 1.2, while that of the control group was 2.5. The number of blood vessels in the aflibercept group was less than that of the control group, and the difference between the two groups reached a significant level (p < 0.05). On the 14th day after fat transplantation, the average number of blood vessels in the aflibercept group was 1.15, while that of the control group was 4.75. The number of blood vessels in the aflibercept group was less than that of the control group, and the difference between the two groups reached a significant level (p < 0.05). On the 21st day after fat transplantation, the average number of blood vessels in the aflibercept group was 1.4, while that of the control group was 3.9. The number of blood vessels in the aflibercept group was less than that of the control group, and the difference between the two groups reached a significant level (p < 0.05). On the 30th day after fat transplantation, the average number of blood vessels in the Aflibercept group was 1.9, while that in the Control group was 2.3. The number of blood vessels in the Aflibercept group was less than that in the Control group, but the difference between the two groups gradually decreased and did not reach a significant level (p>0.05). As the time of fat transplantation was further prolonged, the number of blood vessels in the Aflibercept group and the Control group gradually increased, and the difference further decreased. Table 1 and Figure 2 The results showed that in the first 30 days after fat transplantation, the amount of angiogenesis in the fat grafts of the aflibercept group was less than that in the control group. As the mice were fed for longer periods of time after fat transplantation, the difference in angiogenesis between the two groups gradually increased (before 14 days), and then gradually decreased (after 14 days). The difference between the two groups was still significant 30 days after fat transplantation, indicating that aflibercept can effectively inhibit the angiogenesis of fat grafts.
[0047] On the 3rd day after fat transplantation, the average number of blood vessels in the fat grafts of the Ramuciumab group was 1.05, while that of the Control group was 2.45. The number of blood vessels in the Ramuciumab group was less than that of the Control group, and the difference between the two groups reached a significant level (p < 0.05); on the 7th day after fat transplantation, the average number of blood vessels in the fat grafts of the Ramuciumab group was 1.2, while that of the Control group was 2.5. The number of blood vessels in the Ramuciumab group was less than that of the Control group, and the difference between the two groups reached a significant level (p < 0.05). On the 14th day after fat transplantation, the average number of blood vessels in the Ramuciumab group was 1.35, while that of the Control group was 4.75. The number of blood vessels in the Ramuciumab group was less than that of the Control group, and the difference between the two groups reached a significant level (p < 0.05). On the 21st day after fat transplantation, the average number of blood vessels in the Ramuciumab group was 1.5, while that of the Control group was 3.9. The number of blood vessels in the Ramuciumab group was less than that of the Control group, and the difference between the two groups reached a significant level (p < 0.05). On the 30th day after fat transplantation, the average number of blood vessels in the Ramuciumab group was 1.35, while that in the Control group was 2.3. The number of blood vessels in the Ramuciumab group was less than that in the Control group, and the difference between the two groups was significant (p < 0.05); as the fat transplantation time was further extended, the number of blood vessels in the Ramuciumab group and the control group gradually increased, and the difference further decreased. On the 90th day after fat transplantation, the average number of blood vessels in the Ramuciumab group was 2.15, while that in the Control group was 2.66. The number of blood vessels in the Ramuciumab group was less than that in the Control group, but the difference between the two groups was not significant (p > 0.05). Table 1 and Figure 2 The results showed that in the first 30 days after fat transplantation, the amount of angiogenesis in the fat grafts of the ramucirumab group was less than that of the control group. As the mice were fed for longer periods of time after fat transplantation, the difference in angiogenesis between the two groups gradually increased (before 14 days), and then gradually decreased (after 14 days). The difference between the two groups was still significant 30 days after fat transplantation, indicating that aflibercept can effectively inhibit the angiogenesis of fat grafts.
[0048] 1.2.2 The volume of fat graft was measured by drainage method and the fat graft volume retention rate was calculated. The results are shown in Figure 3 , Figure 4 and Table 2.
[0049] Table 2 Results of fat graft volume changes
[0050]
[0051] Depend on Figure 3It can be seen that in the first 3 days of fat transplantation, the volume changes of fat grafts in the bevacizumab group, aflibercept group, ramucirumab group and control group were not obvious. After the 7th day of fat transplantation, the volume changes of fat grafts in the bevacizumab group, aflibercept group and ramucirumab group were smaller than that in the control group, that is, the fat graft retention rates in the bevacizumab group, aflibercept group and ramucirumab group were higher than those in the control group. This indicates that as blood vessels grow into the fat grafts on the 3rd day, the effects of bevacizumab, aflibercept and ramucirumab in inhibiting angiogenesis begin to appear, and angiogenesis in the bevacizumab group, aflibercept group and ramucirumab group is inhibited, and then the fat graft retention rates in the bevacizumab group, aflibercept group and ramucirumab group are higher than those in the control group. When the mice were raised for more than 7 days, the differences in fat graft retention rates among the bevacizumab group, aflibercept group, ramucirumab group and control group reached a significant level (p < 0.05), and bevacizumab, aflibercept and ramucirumab improved the fat graft retention rate.
[0052] like Figure 4 As shown in Table 2, in the first 7 days of fat transplantation, the volume of the fat grafts in the bevacizumab group and the control group did not change significantly. The reason why the volume of the fat grafts exceeded 100% was that in the very early stage after fat transplantation, due to factors such as inflammation and fat grafts absorbing water, the fat grafts would swell slightly and the volume would increase slightly. On the 14th day of fat transplantation, the volume of the fat grafts in the bevacizumab group was 95% of the initial volume, and the volume of the fat grafts in the control group was 83.3% of the initial volume. The volume change in the bevacizumab group was less than that in the control group, and the volume change of the fat grafts between the two groups reached a significant level (p < 0.05). On the 21st day of fat transplantation, the volume of the fat grafts in the bevacizumab group was 87% of the initial volume, and the volume of the fat grafts in the control group was 81% of the initial volume. The volume change in the bevacizumab group was less than that in the control group. As the feeding time of mice was further extended, the difference between the volume changes of the fat grafts in the bevacizumab group and the control group still reached a significant level (p < 0.05). On the 30th day after fat transplantation, the fat retention rate of the bevacizumab group was not less than 81%, and on the 60th day, the fat retention rate of the bevacizumab group was still as high as 68.9%. On the 90th day, the fat retention rate of the bevacizumab group was still as high as 64.4%, significantly higher than the 54.2% of the control group. The above experimental results fully demonstrate that bevacizumab effectively improves the retention rate of fat grafts after inhibiting angiogenesis.
[0053] In the first 7 days of fat transplantation, the fat graft volume of the aflibercept group and the control group did not change significantly. On the 14th day of fat transplantation, the fat graft volume of the aflibercept group was 88.3% of the initial volume, and the fat graft volume of the control group was 83.3% of the initial volume. There was no significant difference in the volume change between the aflibercept group and the control group. On the 21st day of fat transplantation, the fat graft volume of the aflibercept group was 83.3% of the initial volume, and the fat graft volume of the control group was 81% of the initial volume. There was no significant difference in the fat graft volume change between the aflibercept group and the control group. As the mice were raised for more than 21 days, the difference in fat retention rate between the aflibercept group and the control group gradually emerged. On the 30th day of fat transplantation, the fat graft volume of the aflibercept group was 80% of the initial volume, while the fat retention rate of the control group was 75%. There was a significant difference in the fat graft volume change between the aflibercept group and the control group. On the 60th day after fat transplantation, the fat retention rate of the aflibercept group was 72.2%, while that of the control group was 56.7%. On the 90th day, the fat retention rate of the aflibercept group was still as high as 66.7%, significantly higher than the 54.2% of the control group. The above experimental results fully demonstrate that aflibercept effectively improves the retention rate of fat grafts after inhibiting angiogenesis.
[0054] In the first 7 days of fat transplantation, the volume of fat grafts in the Ramuciumab group and the control group did not change significantly. The reason why the volume of fat grafts exceeded 100% was that in the very early stage after fat transplantation, due to factors such as inflammation and fat grafts absorbing water, the fat grafts would swell slightly and the volume would increase slightly. As the fat transplantation time exceeded 7 days, the difference in the volume change of fat grafts between the Ramuciumab group and the control group gradually became obvious. On the 14th day of fat transplantation, the volume of fat grafts in the Ramuciumab group was 96.7% of the initial volume, and the volume of fat grafts in the control group was 83.3% of the initial volume, and the difference in the volume change of fat grafts between the two groups reached a significant level (p < 0.05). On the 21st day of fat transplantation, the volume of fat grafts in the Ramuciumab group was 95% of the initial volume, and the volume of fat grafts in the control group was 81% of the initial volume. The volume change in the Ramuciumab group was significantly less than that in the control group. On the 30th day of fat transplantation, the fat graft volume of the Ramuciumab group was 86.7% of the initial volume, and the fat graft volume of the control group was 75% of the initial volume. On the 60th day of fat transplantation, the fat retention rate of the Ramuciumab group was not less than 71%. At 90 days, the fat retention rate of the Ramuciumab group was still as high as 65.8%, significantly higher than the 54.2% of the control group. The above experimental results fully demonstrate that Ramuciumab effectively improves the fat graft retention rate after inhibiting angiogenesis.
[0055] In summary, Example 1 demonstrates that anti-angiogenic drugs improve the retention rate of fat grafts by inhibiting the early vascularization of fat grafts. The inventors have found through experiments that, based on a similar mechanism, that is, by inhibiting the vascularization of grafts, anti-angiogenic drugs can effectively improve the retention rate of other soft tissue grafts such as skin grafts, tendon grafts, muscle grafts, ligament grafts, joint capsule grafts, synovial capsule grafts, corneal grafts and nerve grafts.
[0056] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.
Claims
1. Application of anti-angiogenic drugs in improving the retention rate of soft tissue grafts.
2. The application of anti-angiogenic drugs in the preparation of products for improving the retention rate of soft tissue grafts.
3. The use according to claim 1 or 2, characterized in that: The anti-angiogenesis drug includes one or more of VEGF monoclonal antibody, soluble VEGFR, humanized VEGFR-2 monoclonal antibody or small molecule tyrosine kinase inhibitor.
4. The use according to claim 3, characterized in that: The VEGF monoclonal antibody includes bevacizumab, the soluble VEGFR includes aflibercept, the humanized VEGFR-2 monoclonal antibody includes ramucirumab, and the small molecule tyrosine kinase inhibitor includes etanercept.
5. The use according to claim 1 or 2, characterized in that: The dosage of the anti-angiogenesis drug is 1 mL of the soft tissue graft combined with 0.5-10 mg of the anti-angiogenesis drug.
6. The use according to claim 4, characterized in that: The anti-angiogenic drug is bevacizumab, and the dosage of the bevacizumab is 1.25-6.25 mg per 1 mL of the soft tissue graft; and / or, The anti-angiogenic drug is aflibercept, and the dosage of the aflibercept is 2-10 mg per 1 mL of the soft tissue graft; and / or, The anti-angiogenic drug is ramucirumab, and the dosage of ramucirumab is 0.5-2.5 mg per 1 mL of the soft tissue graft; and / or, The anti-angiogenic drug is Etan, and the dosage of the Etan is 1 mL of the soft tissue graft combined with 1.0-2.5 mg of the Etan.
7. The use according to claim 1, characterized in that: The soft tissue graft includes one or more of a skin graft, a fat graft, a tendon graft, a muscle graft, a ligament graft, a joint capsule graft, a synovial capsule graft, a corneal graft or a nerve graft.
8. The use according to claim 7, characterized in that: The fat graft is autologous fat or allogeneic fat, preferably autologous fat.
9. The use according to claim 1 or 2, characterized in that: The anti-angiogenesis drug is applied to an animal transplanted with a soft tissue graft, or the soft tissue graft to be transplanted is treated with the anti-angiogenesis drug.
10. The use according to claim 9, characterized in that: The animals include humans and non-human mammals.
Citation Information
Patent Citations
Methods of extending corneal graft survival
CA2476994A1
Article of manufacture comprising aflibercept or ziv-aflibercept
CN104853763A
Allograft tolerance without the need for systemic immune suppression
CN110869494A
Methods of extending corneal graft survival
US20030180294A1
Treatment response to Anti-angiogenic therapies
US20120225063A1
